NCT05420636 is a Phase 2 clinical trial of Iadademstat in Small-cell Lung Cancer, sponsored by Fox Chase Cancer Center.

Who is sponsoring NCT05420636?

NCT05420636 is sponsored by Fox Chase Cancer Center.

What drugs are being tested in NCT05420636?

Interventions in NCT05420636: Iadademstat, Paclitaxel.

What condition does NCT05420636 study?

NCT05420636 studies Small-cell Lung Cancer, Neuroendocrine Carcinoma.

Is NCT05420636 still recruiting?

NCT05420636 is currently terminated. Last updated 30 July 2025.

Last reviewed 2025-07-30 · How we verify

NCT05420636

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Terminated Phase 2 Last updated 30 July 2025

What this trial tests

Phase 2 trial testing Iadademstat in Small-cell Lung Cancer in 20 participants. Terminated before completion.

Timeline

21 December 2022

Primary endpoint
23 July 2025

23 July 2025

Quick facts

Lead sponsor	Fox Chase Cancer Center
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	21 December 2022
Primary completion	23 July 2025
Estimated completion	23 July 2025
Sites	3 locations across United States

Drugs / interventions tested

Iadademstat — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Small-cell Lung Cancer — all drugs for Small-cell Lung Cancer →
Neuroendocrine Carcinoma — all drugs for Neuroendocrine Carcinoma →

Sponsor

Fox Chase Cancer Center — full company profile →

Who can join

18 and older, any sex, with Small-cell Lung Cancer or Neuroendocrine Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-randomized single-arm, two cohorts, phase II study of iadademstat in combination with weekly paclitaxel in patients with relapse/refractory SCLC or extrapulmonary G3 Neuroendocrine Carcinomas. A total of 42 patients with SCLC (21 patients) and G3 NEC (21 patients) will be enrolled (including those enrolled in the safety lead-in portion).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials.
Noce B, Di Bello E, Fioravanti R, Mai A. · · 2023 · cited 78× · PMID 36817147 · DOI 10.3389/fphar.2023.1120911
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Yin N, Li X, Zhang X, Xue S, et al · · 2024 · cited 48× · PMID 38773064 · DOI 10.1038/s41392-024-01826-z
Pharmacological targeting of the cancer epigenome.
Mabe NW, Perry JA, Malone CF, Stegmaier K. · · 2024 · cited 36× · PMID 38937652 · DOI 10.1038/s43018-024-00777-2
20 years of histone lysine demethylases: From discovery to the clinic and beyond.
Gray ZH, Honer MA, Ghatalia P, Shi Y, et al · · 2025 · cited 21× · PMID 40185081 · DOI 10.1016/j.cell.2025.02.023
Informed by Cancer Stem Cells of Solid Tumors: Advances in Treatments Targeting Tumor-Promoting Factors and Pathways.
MacLean MR, Walker OL, Arun RP, Fernando W, et al · · 2024 · cited 21× · PMID 38612911 · DOI 10.3390/ijms25074102
Chemical Inhibitors Targeting the Histone Lysine Demethylase Families with Potential for Drug Discovery.
Das ND, Niwa H, Umehara T. · · 2023 · cited 14× · PMID 36975603 · DOI 10.3390/epigenomes7010007
Novel Therapeutic Options for Small Cell Lung Cancer.
Canova S, Trevisan B, Abbate MI, Colonese F, et al · · 2023 · cited 13× · PMID 37870696 · DOI 10.1007/s11912-023-01465-7
Therapeutic targeting of chromatin alterations in leukemia and solid tumors.
Perner F, Berg T, Sasca D, Mersiowsky SL, et al · · 2026 · cited 11× · PMID 40181550 · DOI 10.1002/ijc.35389

Verify or expand the search:

Other trials of Iadademstat

Trials testing the same drug.

NCT06661915 — A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) · Phase 2 · recruiting
NCT06287775 — Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) a · Phase 1, PHASE2 · recruiting
NCT06514261 — Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) f · Phase 1 · recruiting
NCT06357182 — Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia · Phase 1 · recruiting
NCT05546580 — Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) · Phase 1 · recruiting

Other recruiting trials for Small-cell Lung Cancer

Currently open trials in the same condition.

NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT07218146 — A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVAT · Phase 3 · recruiting
NCT07005128 — A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in Fi · Phase 3 · recruiting
NCT06424067 — Phase 2 Study of Fingolimod in Lung Cancers · Phase 2 · recruiting
NCT06957314 — A Study of Hospital-at-Home for People Receiving Tarlatamab · NA · recruiting

Other Fox Chase Cancer Center trials

Trials by the same sponsor.

NCT07455032 — Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous · Phase 1 · recruiting
NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
NCT07221058 — Adaptive Radiation Boost for Rectal Cancer · Phase 1 · recruiting
NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
NCT07219303 — Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05420636 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fox Chase Cancer Center
Last refreshed: 30 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05420636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing